Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada

Amdahl, Jordan; Diaz, Jose; Park, J.; Nakhai-Pour, Hamid Reza; Delea, Thomas E.

doi:10.3747/co.23.2244

Cited by 47 publications

(46 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fortunately, economic outcomes were not sensitive to all parameters related to AEs. Sixth, due to the absence of head-to-head trials, the current analysis did not include other competing agents, such as pazopanib that is a cost-effective option in comparison with sunitinib [ 27 , 35 , 41 ]. The current study needs to be updated by including these novel competing alternatives.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Wu¹,

Zhang²,

Sun³

2018

j. immunotherapy cancer

View full text Add to dashboard Cite

BackgroundNivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC). The current study aimed to assess the cost-effectiveness of nivolumab plus ipilimumab for first-line treatment of advanced RCC from the payer perspectives high- and middle-income regions.MethodsA decision-analytic model was constructed to evaluate the health and economic outcomes of first-line sunitinib and nivolumab plus ipilimumab treatment associated with advanced RCC. The clinical and utility data were obtained from published reports. The cost data were acquired for the payer perspectives of the United States (US), United Kingdom (UK), and China. Sensitivity analyses were performed to test the uncertainties of the results. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were used.ResultsNivolumab plus ipilimumab gained 0.70–0.76 QALYs compared with sunitinib. Our analysis determined the following ICERs for nivolumab plus ipilimumab over sunitinib in first-line advanced RCC treatment: US $ 85,506 /QALY; UK $ 126,499/QALY; and China $ 4682/QALY. Sensitivity analyses found the model outputs to be most affected for body weight and for the prices of nivolumab, sunitinib and ipilimumab.ConclusionsNivolumab plus ipilimumab as first-line treatment could gain more health benefits for advanced RCC in comparison with standard sunitinib, which is considered to be cost-effective in the US and China but not in the UK.Electronic supplementary materialThe online version of this article (10.1186/s40425-018-0440-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Mean health utility scores for PFS and PD state were derived from published literature (Table 1 ) [ 24 , 29 , 41 , 42 ]. The disutility values due to grade 1/2 and 3/4 AE were included in this analysis [ 41 ].…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Wu¹,

Zhang²,

Sun³

2018

j. immunotherapy cancer

View full text Add to dashboard Cite

show abstract

“…Third, because of the lack of complete QoL data to calculate the utility values, we corrected the utility values by considering the disutility values of AEs, and only grade 3 and 4 AEs were included, which might lead to overestimates or underestimates of the utility values. Fourth, because of the absence of head-to-head trials, other competing strategies were not included, such as pazopanib, a more cost-effective treatment than that using sunitinib [7,43,44]. Fifth, this trial-based study could not wholly track the natural disease course in the real world.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

Ding

Hu²,

Yin

et al. 2020

The Oncologist

View full text Add to dashboard Cite

Background. The data from the phase III clinical trial KEYNOTE-426 indicated that pembrolizumab plus axitinib compared with sunitinib could generate clinical benefits in patients with previously untreated advanced renal cell carcinoma (RCC). Given the incremental clinical benefits, we examined the potential cost-effectiveness of pembrolizumab plus axitinib versus sunitinib in the first-line setting for patients with advanced RCC from the U.S. payers' perspective. Materials and Methods. Cost and health outcomes were estimated at a willingness-to-pay (WTP) threshold of $100,000 to $150,000 per quality-adjusted life-year (QALY). One-way and probabilistic sensitivity analyses were performed by varying potentially modifiable parameters, and additional subgroup analyses were performed as well. Results. Upon our analyses, the total treatment costs in the pembrolizumab plus axitinib and sunitinib groups were $522,796 and $348,424 and the QALYs gained 2.90 and 1.72, respectively. In the base-case analysis, compared with receiving sunitinib, patients with advanced RCC receiving pembrolizumab plus axitinib gained 1.18 more QALYs at an incremental cost-effectiveness ratio of $148,676/QALY. The results of subgroup analyses demonstrated that pembrolizumab plus axitinib was most cost-effective for patients who had one organ with metastasis. Conclusion.

show abstract

“…22 The disutility values due to grade 1/2 and 3/4 AEs were included in this analysis. 23 All AEs were assumed to be incurred in the first cycle. The duration-adjusted disutility was subtracted from the baseline PFS utility.…”

Section: Cost and Utility Inputsmentioning

confidence: 99%

Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Wu¹,

Shi

2020

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: Maintenance therapy with the PARP inhibitor olaparib for metastatic pancreatic cancer (MPC) with a germline BRCA1 or BRCA2 mutation has been shown to be effective. We aimed to evaluate the cost-effectiveness of maintenance olaparib for MPC from the US payer perspective. Materials and Methods: A partitioned survival model was adopted to project the disease course of MPC. Efficacy and toxicity data were gathered from the Pancreas Cancer Olaparib Ongoing (POLO) trial. Transition probabilities were estimated from the reported survival probabilities in each POLO group. Cost and health preference data were derived from the literature. The incremental cost-utility ratio, incremental net-health benefit, and incremental monetary benefit were measured. Subgroup analysis, one-way analysis, and probabilistic sensitivity analysis were performed to explore the model uncertainties. Results: Maintenance olaparib had an incremental cost-utility ratio of $191,596 per additional progression-free survival (PFS) quality-adjusted life-year (QALY) gained, with a high cost of $132,287 and 0.691 PFS QALY gained, compared with results for a placebo. Subgroup analysis indicated that maintenance olaparib achieved at least a 16.8% probability of cost-effectiveness at the threshold of $200,000/QALY. One-way sensitivity analyses revealed that the results were sensitive to the hazard ratio of PFS and the cost of olaparib. When overall survival was considered, maintenance olaparib had an incremental cost-utility ratio of $265,290 per additional QALY gained, with a high cost of $128,266 and 0.483 QALY gained, compared with results for a placebo. Conclusions: Maintenance olaparib is potentially cost-effective compared with placebo for patients with a germline BRCA mutation and MPC. Economic outcomes could be improved by tailoring treatment based on individual patient factors.

show abstract

Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada

Abstract: Background In Canada and elsewhere, pazopanib and sunitinib-tyrosine kinase inhibitors targeting the vascular

Cited by 47 publications

References 38 publications

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Contact Info

Product

Resources

About